by Clinical Neuropsychologist | Wednesday, July 17, 2024 | Dementia
Abstract INTRODUCTION Physical frailty is reversible, but little is known about the sustainability of frailty remission and its impact on dementia. METHODS Data were derived from the National Health and Aging Trends Study (NHATS) (2011 to 2021). Physical frailty was...
by Clinical Neuropsychologist | Wednesday, July 17, 2024 | Dementia
Abstract INTRODUCTION Plasma phosphorylated tau (p-tau)217 is a promising biomarker for Alzheimer’s disease (AD) diagnosis, but its clinical implementation remains challenging. We propose a strategy based on Bayes’ theorem and test it in real-life memory...
by Clinical Neuropsychologist | Wednesday, July 17, 2024 | Dementia
Abstract INTRODUCTION Consensus definitions of meaningful within-patient change (MWPC) on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) are needed. Existing estimates use clinician-rated anchors in clinically diagnosed Alzheimer’s disease (AD) populations....
by Clinical Neuropsychologist | Wednesday, July 17, 2024 | Dementia
Abstract INTRODUCTION Aging is one of the risk factors for the early onset of Alzheimer’s disease (AD). We previously discovered that the age-dependent increase in Ubiquitin Conjugating Enzyme E2 N (UBE2N) plays a role in the accumulation of misfolded proteins...
by Clinical Neuropsychologist | Tuesday, July 16, 2024 | Dementia
Abstract Extracellular vesicles (EVs) hold promise as a source of disease biomarkers. The diverse molecular cargo of EVs can potentially indicate the status of their tissue of origin, even against the complex background of whole plasma. The main tools currently...
by Clinical Neuropsychologist | Saturday, July 13, 2024 | Dementia
Abstract INTRODUCTION Despite parallel research indicating amyloid-β accumulation, alterations in cortical neurophysiological signaling, and multi-system neurotransmitter disruptions in Alzheimer’s disease (AD), the relationships between these phenomena remains...
